Leadership Team
Our leadership team brings an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to your drug development process
Former CEO of Immune Design, previously Elan, Eli Lilly, and Mayo Clinic
Former Chief Regulatory Affairs EQRX, previously Foundation Medicine and Roche
Former VP, Scientific Affairs and Head of AbbVie Ventures, AbbVie
Former VP of Clinical Development, BeiGene, previously MedImmune, AstraZeneca, and Eli Lilly
Former CBO, Nuvelution, previously Corporate Development at IQVIA
Former VP of Development Operations, PPD, previously Nucana
Former SVP Operations and Chief Compliance Officer, Nuvelution, previously IQVIA
Former Healthcare Private Equity Investor, Carlyle, previously Morgan Stanley
Advisory Committee
Board Of Directors
Board Director for Curia, Millicent, PPD (former), Saama, TriNetX, WellDyneRx, and others
Board Director for Cymabay Jasper, Orbus, SFJ, Tizona Vaxcyte Vera, and others
Board Director for Anjarium, Exicure, Gynesonics, NuCana, Reneo, Spruce, and others
Board Director for Curia, Medline, Ortho Clinical Diagnostics, PPD (former), Resonetics, Sedgwick, and others
How We Help
Launch Therapeutics offers pharmaceutical and biotech partners a variety of innovative models that provide capital, development expertise, and access to additional resources. These models offer an aligned and efficient approach to help finance and develop late-stage therapies and accelerate the path to regulatory approval. Launch Tx’s team of experts brings an unrivaled combination of immense commitment, decades of experience, and enthusiastic passion to their work.
Сapital
Bespoke deal structures taking combination of clinical, regulatory, and commercial risks
Resources
Team with deep clinical and regulatory expertise with access to an expansive network
Acceleration
Disruptive model accelerating clinical development and regulatory timelines
Demonstrated Trust and Belief
Launch Therapeutics (Launch Tx) is backed by the respected and experienced professionals at Carlyle and its life sciences franchise, Abingworth. Their investments demonstrate the deep trust and belief they have in Launch Tx to disrupt the development paradigm and expedite the pathway for therapies to be approved and into the hands of patients who need them.
Carlyle and Abingworth, along with our CEO, Anshul Thakral, formed Launch Therapeutics in 2022. By combining the global network of Carlyle and Abingworth with the seasoned team of professionals at Launch Tx, both pharmaceutical and biotech companies have an ideal partner to advance their late-stage clinical programs.
